Linzess (linaclotide) is a prescription medication approved by the Food and Drug Administration (FDA) to treat certain types of constipation. Most Medicare Part D plans provide coverage for the drug ...

Shares of Ironwood Pharmaceuticals IRWD have witnessed a sharp decline over the past month, primarily due to softer sales of ...

Ironwood Pharmaceuticals IRWD has been witnessing improved demand for its sole marketed product, Linzess (linaclotide), in recent quarters. The company markets Linzess in the United States in ...

Please provide your email address to receive an email when new articles are posted on . The FDA has granted priority review to a supplemental new drug application for Linzess for the treatment of ...

Allergan and Ironwood are going where GI commercials have not gone before: into the bathroom. A new TV ad for Linzess, begun last week, features two different people sitting on the toilet—viewers see ...

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) is one of the 7 best small-cap drug manufacturing stocks to buy according to ...

Ironwood Pharmaceuticals’ IRWD sole marketed product, Linzess (linaclotide), is approved for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients aged ...

Credit: Shutterstock. Linzess is a guanylate cyclase-C agonist. The Food and Drug Administration (FDA) has approved Linzess ® (linaclotide) for the treatment of functional constipation (FC) in ...

There’s a new competitor to Allergan and Ironwood’s Linzess on the block in the chronic idiopathic constipation (CIC) market. And the way some industry watchers see it, it may not be long before the ...

Linzess (linaclotide), a medication for irritable bowel syndrome (IBS) with constipation or chronic idiopathic constipation is now available in American pharmacies, Ironwood Pharmaceuticals Inc. and ...